Induction and function of Fc epsilon RII on YT cells; possible role of ADF/thioredoxin in Fc epsilon RII expression.
The regulation of low-affinity Fc receptor for IgE (Fc epsilon RII) and the characteristics of both membrane and soluble forms of Fc epsilon RII were studied using YT cell line. We found that YT cells, a human NK like cell line, expressed Fc epsilon RII after IL-1 stimulation. Cross-linking of Fc epsilon RII on IL-1-stimulated YT cells as well as the transfectant of Fc epsilon RII-cDNA (YTSER) resulted in the up-regulation of IL-2R alpha (p55/Tac). A 59 kDa protein phosphorylated at tyrosine residues was co-immunoprecipitated with Fc epsilon RII from YTSER lysate using H107 anti-Fc epsilon RII mAb. YTSER not only expressed Fc epsilon RII on their surface but also secreted soluble form of Fc epsilon RII (sFc epsilon RII/sCD23; IgE binding factor). Affinity purification revealed that sFc epsilon RII released from YTSER is heterogeneous and consisted of several proteins differing in molecular weight. Both EBV+ B cells and HTLV-1+ T cells are high producers of ATL derived factor (ADF)/thioredoxin (TRX) and express Fc epsilon RII and IL-2R alpha respectively. To clarify the mechanism of Fc epsilon RII and IL-2R alpha induction by ADF/TRX, we examined the effect of ADF/TRX on the bindability of nuclear factor kappa B (NF-kappa B), which is known to regulate IL-2R alpha gene expression. In the gel shift assay, ADF/TRX was shown to enhance the bindability of NF-kappa B to its responsive element.
Sorachi
K
K
Second Division of Internal Medicine, Faculty of Medicine, Kyoto University Medical School, Japan.
Sugie
K
K
Maekawa
N
N
Takami
M
M
Kawabe
T
T
Kumagai
S
S
Imura
H
H
Yodoi
J
J
D001483:Base Sequence; D002460:Cell Line; D002852:Chromatography, Ion Exchange; D016207:Cytokines; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000378:metabolism* / Q000502:physiology; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000276:immunology*; D010084:Oxidation-Reduction / Q000187:drug effects; D010766:Phosphorylation; D011518:Proto-Oncogene Proteins / Q000276:immunology; D051076:Proto-Oncogene Proteins c-fyn; D017455:Receptors, IgE / Q000096:biosynthesis* / Q000502:physiology*; D013879:Thioredoxins / Q000276:immunology*; D014162:Transfection; D014443:Tyrosine / Q000378:metabolism
D016207:Cytokines; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D017455:Receptors, IgE; C055533:adult T cell leukemia-derived factor; D007073:Immunoglobulin E; D014443:Tyrosine; D013879:Thioredoxins; C494957:FYN protein, human; D051076:Proto-Oncogene Proteins c-fyn